USPTO serial 79401832
3DµS
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Jul 15, 2025
- Examiner
- LAM, HAI-LY HUYNH
- Law office
- Historical data usage
What this means
Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.
Need help with 3DµS?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Alex Patel
Alex Patel Patel IP, P.C.20700 Ventura Blvd., Suite 235Woodland Hills, CA 91364United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Veterinary preparations, namely, veterinary vaccines, greases for veterinary purposes, antibiotics for veterinary purposes, bacterial preparations for veterinary purposes, veterinary diagnostic reagents, antibodies for veterinary purposes, and anti-infective products for veterinary use; dietetic foods adapted for medical purposes; sugar for medical purposes; dental resin for temporary bridges, crowns and veneers; pharmaceutical preparations for the treatment of bone diseases; biological tissue cultures for medical purposes; fever blister treatment preparations; dysmenorrhea treatment preparations; pharmaceutical preparations for the central nervous system; oral analgesics; anticoagulants; tumor suppressing agents; pharmaceutical preparations, namely, a drug delivery system comprising polymer-based oral tablets for the continuous release of a wide variety of therapeutic agents; pharmaceutical preparations for the treatment of musculoskeletal disorders; pharmaceutical preparations for inducing erections; stimulants for the central nervous system; pharmaceutical preparations for treating allergies; anti-diabetic pharmaceuticals; calcium channel blockers; medicinal preparations for the mouth to be applied in the form of tablets; pharmaceutical preparations for the prevention and treatment of cancer; niacinamide preparations for the treatment of acne; pharmaceutical preparations for suppressing tumors; pharmaceutical preparations for treating hypoglycemia; antihypertensives; chemotherapeutics; antivirals; anti-infectives; chemico-pharmaceutical preparations for the treatment of cancer, oncological diseases, cardiovascular and cerebrovascular diseases, respiratory diseases, genitourinary diseases, neurological diseases, immune system related diseases, gastrointestinal diseases, musculoskeletal diseases and endocrine metabolism-related diseases; living cells for medical use; parathyroid hormone preparations; contraceptive preparations; medicines for the treatment of cardiovascular and cerebrovascular diseases; hypnotic sedatives; pharmaceutical products for treating respiratory diseases | ACTIVE | — |
| 007 | Machines for the pharmaceutical processing industry, namely, print heads for 3D printers for drugs and vaccine preparations, print heads for pharmaceutical drug and vaccine printing machines, industrial robots for conveying of drugs and vaccine preparations, and packaging machines for drugs and vaccine preparations; machines for the pharmaceutical processing industry, namely, for producing drug and vaccine capsules and tablets and mixing machines for drugs and vaccines; 3D printers * for pharmaceutical processing industry; * 3D bioprinters * for pharmaceutical processing industry * | ACTIVE | — |
| 042 | Scientific research for medical purposes in the field of cancerous diseases; pharmaceutical research services; testing of pharmaceuticals; research and development services in the field of medicines; development of pharmaceutical preparations and medicines; pharmaceutical research and development; pharmaceutical drug development services; pharmaceutical product evaluation; conducting early evaluations in the field of new pharmaceuticals; technical research in the field of pharmaceutical studies; quality testing of pharmaceutical product; advisory services relating to material testing | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Triastek, Inc.
- Other trademarks owned by Triastek, Inc.
- Other trademarks owned by Triastek, Inc.
- Other trademarks in Class 005
- Other trademarks in Class 007
- Other trademarks in Class 042
- Similar marks named 3DµS
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Mar 3, 2026 | NURC | NOTICE OF UPDATED REGISTRATION CONFIRMATION EMAILED | — |
| Feb 26, 2026 | FINO | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| Feb 11, 2026 | FICS | FINAL DISPOSITION NOTICE SENT TO IB | — |
| Feb 11, 2026 | LIME | LIMITATION FROM THE IB EXAMINED AND ENTERED | — |
| Feb 11, 2026 | FIMP | FINAL DISPOSITION PROCESSED | — |
| Feb 11, 2026 | COC. | CORRECTION UNDER SECTION 7 - PROCESSED | — |
| Feb 11, 2026 | APRE | CASE ASSIGNED TO POST REGISTRATION PARALEGAL | — |
| Jan 22, 2026 | OPNX | NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB | — |
| Jan 7, 2026 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Jan 7, 2026 | OPNR | NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB | — |
| Oct 15, 2025 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| Aug 22, 2025 | LIMG | LIMITATION OF GOODS RECEIVED FROM IB | — |
| Jul 15, 2025 | NRCC | NOTICE OF REGISTRATION CONFIRMATION EMAILED | — |
| Jul 15, 2025 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Jun 25, 2025 | ETOP | EXTENSION OF TIME TO OPPOSE PROCESS - TERMINATED | — |
| May 15, 2025 | ETOF | EXTENSION OF TIME TO OPPOSE RECEIVED | — |
| Apr 15, 2025 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Apr 15, 2025 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Apr 9, 2025 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Mar 21, 2025 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Feb 25, 2025 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Feb 25, 2025 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Feb 25, 2025 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Feb 25, 2025 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Feb 24, 2025 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Feb 24, 2025 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Feb 24, 2025 | ERFR | TEAS REQUEST FOR RECONSIDERATION RECEIVED | — |
| Jan 17, 2025 | GNFN | NOTIFICATION OF FINAL REFUSAL EMAILED | — |
| Jan 17, 2025 | GNFR | FINAL REFUSAL E-MAILED | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Jan 17, 2025 | CNFR | FINAL REFUSAL WRITTEN | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Dec 20, 2024 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Dec 20, 2024 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Dec 20, 2024 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Oct 8, 2024 | RFNT | REFUSAL PROCESSED BY IB | — |
| Sep 17, 2024 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Sep 16, 2024 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Sep 14, 2024 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Sep 13, 2024 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Sep 11, 2024 | DOCK | ASSIGNED TO EXAMINER | — |
| Aug 19, 2024 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Aug 19, 2024 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Aug 15, 2024 | LIMI | LIMITATION FROM ORIGINAL APPLICATION ENTERED | — |
| Aug 8, 2024 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |